Common (affects between 1 and 10 in 100 patients)
Uncommon (affects between 1 and 10 in 1,000 patients)
Rare (affects between 1 and 10 in 10,000 patients)
Unknown frequency
Venlafaxina Combix can sometimes cause unwanted effects that you may not be aware of, such as increased blood pressure or abnormal heart rate; mild changes in liver enzyme levels, sodium, or cholesterol. Less frequently, Venlafaxina Combix can reduce the function of platelets in the blood, which can increase the risk of bleeding or bruising. Therefore, your doctor may wish to perform occasional blood tests, particularly if you have been taking Venlafaxina Combix for a long time.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicinal Products for Human Use:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging, after CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Venlafaxina Combix
The active ingredient is venlafaxine. Each tablet contains 84.84 mg of hydrochloride of venlafaxine equivalent to 75 mg of venlafaxine.
The other components (excipients) are: microcrystalline cellulose (E460i), lactose monohydrate, sodium glycinate starch, magnesium stearate (E470b), yellow iron oxide (E172), and brown iron oxide (E172).
Appearance of Venlafaxina Combix and content of the container
Venlafaxina Combix 75 mg is presented in the form of oblong beige tablets, speckled, scored on one side and smooth on the other.
Venlafaxina Combix 75 mg is presented in containers containing 60 tablets.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Laboratorios Combix, S.L.U.
C/ Badajoz 2. Edificio 2.
28223 Pozuelo de Alarcón (Madrid)
Spain
Responsible for manufacturing
Combino Pharm S.L.
Fructuós Gelabert 6-8
08970 Sant Joan Despí
Barcelona
SPAIN
Ó
Combino Pharm (Malta) Ltd.
HF 60, Hal Far Industrial Estate
BBG07 Hal Far
MALTA
Ó
ZYDUS FRANCE
Zac Les Hautes Pätures
Parc d´Activités des Pleupliers
25 rue des Pleupliers
92000 Nanterre (France)
Ó
Centre Spécialités Pharmaceutiques
ZAC des Suzots
35 rue de la Chapelle
63450 Saint Amant Tallende
France
This leaflet has been approved in May 2023.
"Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)" http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.